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     ABSTRACT 
 Drug transporters have been suggested to be involved in various aspects of 
pharmacokinetics, including absorption, distribution and excretion. Identification 
and characterization of drug transporters have given us a scientific basis for 
understanding drug disposition, as well as the molecular mechanisms of drug 
interaction and inter-individual/inter-species differences. On the other hand, 
regulatory mechanisms of drug transporters are still poorly understood, and 
information is limited to induction and down-regulation of drug transporters by 
various microsomal enzyme inducers. Little is known about the molecular 
machinery that directly interacts with the drug transporters. As a first step to clarify 
such molecular mechanisms, recent studies have identified PDZ 
(PSD-95/Discs-large/ZO-1) domain-containing proteins that directly interact with 
the so-called PDZ binding motif located at the C-terminus of drug transporters. 
Some of the PDZ proteins have been suggested to regulate transporters via at least 
two pathways, i.e., stabilization at the cell-surface and direct modulation of 
transporter function. Therefore, it is possible that membrane transport of therapeutic 
agents is not only governed by the drug transporters themselves, but also indirectly 
by PDZ proteins. The PDZ proteins are classified as a family, the members of 
which are thought to have distinct, but also redundant physiological roles. The 
purpose of this review article is to summarize the available knowledge on protein 
interactions and functional modulation of drug transporters.  
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1. Overview 
1-1) Introduction 
Recent progress in molecular biology has led to the identification 
of various types of drug transporters which accept therapeutic agents as 
substrates. Drug transporters are generally classified into the SLC (solute 
carrier) and ABC (ATP-binding cassette) superfamilies. These drug 
transporters are believed to be directly involved in various aspects of drug 
disposition, such as absorption, distribution and excretion of drugs (Sai and 
Tsuji 2004; Shitara et al., 2004; Marzolini et al., 2004; Hagenbuch and 
Meier 2003; Jonker and Schinkel 2004). However, little is yet known about 
how these transporters are organized in the plasma membranes, and how 
their expression and function are regulated. Protein-protein interaction is 
involved in many biological events, including signal transduction, 
intracellular trafficking, scaffold formation for protein networks, cellular 
polarization and protein turnover. In this review article, therefore, we 
summarize recent findings on direct interaction of drug transporters with 
so-called adaptor proteins that contain PDZ (PSD-95/Discs-large/ZO-1) 
domains in their structures (Gisler et al., 2003; Anzai et al., 2004; Kato et 
al., 2004, 2005) and discuss the physiological roles of these PDZ domain 
containing proteins, including their expression, localization and effect on 
membrane transporters. Finally, we review the available information on 
peroxisome proliferator-activated receptor (PPAR)-α as a transcriptional 
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factor that affects gene expression of both drug transporters and PDZ 
proteins. 
 
1-2) Significance of identifying protein-transporter interactions 
 An understanding of protein-protein interactions involving drug 
transporters would have various advantages. Firstly, it would help to 
elucidate the molecular machinery that ensures vectorial transport of 
nutrients and xenobiotics. Epithelial cells, especially in kidney and small 
intestine, play fundamental roles in the overall absorption of neutrients, and 
in the secretion of xenobiotics and metabolites (Fig. 1). It is well 
established that transporters play fundamental roles in such vectorial 
transport. In renal proximal tubules of rodents, for example, both organic 
cation transporter (OCT) 1 and OCT2 are localized on basolateral 
membranes and are involved in uptake of organic cations from circulating 
blood, whereas organic cation/carnitine transporter (OCTN) 1 and OCTN2 
are localized on apical membranes and are proposed to be involved in renal 
secretion of those compounds into the urine (Jonker and Schinkel 2004; 
Wright 2005; Ohashi et al., 2001; Tamai et al., 2004) (Fig. 1). These 
OCT/OCTN family members recognize various types of organic cations as 
substrates (Jonker and Schinkel 2004; Wright 2005; Tamai et al., 2000) 
(Fig. 1). OCTN2 and OCTN1 are also involved in reabsorption of carnitine 
from the tubular duct space (Nezu et al., 1999; Tamai et al., 1998, 2000) 
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(Fig. 1). To obtain such vectorial transport of xenobiotics and nutrients (Fig. 
1), OCT/OCTN family members should be appropriately targeted to either 
basolateral or apical plasma membranes (Fig. 1). However, the molecular 
mechanisms of intracellular trafficking of the transporters are poorly 
understood. Protein-protein interaction research may thus throw light on 
intrinsic mechanisms governing drug absorption and secretion by clarifying 
intracellular trafficking mechanisms of the transporters. 
Certain types of therapeutic agents can also be recognized by the 
nutrient transporters in the small intestine. For example, β-lactam 
antibiotics, ACE inhibitors and bestatin are recognized by oligopeptide 
transporter (PEPT) 1 which is expressed on apical membranes of small 
intestinal absorptive epithelial cells and thought to be involved in 
absorption of peptides and therapeutic agents. and renal tubular epithelial 
cells (Tsuji and Tamai, 1996; Daniel 2004; Nielsen and Brodin 2003; Han 
and Amidon 2000). Monocarboxylate transporter (MCT) 1 expressed on 
apical membranes in the small intestine could also be involved in intestinal 
absorption of anionic compounds (Tsuji and Tamai 1996). Organic anion 
transporting polypeptide (OATP)-B, which recognizes estrone sulfate as an 
endogenous substrate, is also expressed on the apical membrane in human 
small intestine and transports various types of hydrophobic organic anions 
(Kobayashi et al., 2003; Nozawa et al., 2004). On the other hand, 
P-glycoprotein and multidrug resistance associated protein (MRP) 2 are 
- 6 - 
involved in, the secretion of various types of therapeutic agents in the small 
intestine (Benet et al., 2004; Kunta and Sinko 2004; Sai and Tsuji 2004). In 
the liver and kidney, numerous studies have confirmed functional 
expression of OATP, organic anion transporter (OAT) and OCT/OCTN 
family members on basolateral and apical surfaces of hepatocytes and renal 
tubular epithelial cells, where they are involved in vectorial transport of 
numerous therapeutic agents (Sai and Tsuji 2004; Shitara et al., 2004; 
Marzolini et al., 2004; Hagenbuch and Meier 2003; Jonker and Schinkel 
2004). Protein-protein interaction research may thus uncover intrinsic 
mechanisms governing drug absorption and secretion in these organs, e.g., 
trafficking and retention of the transporters themselves.   
Secondly, adaptor proteins which can bind to drug transporters 
may affect the cell-surface expression, function and/or intracellular 
trafficking of the transporters, thereby influencing drug disposition. 
Pioneering studies have indicated that PDZ (PSD-95/Discs-large/ZO-1) 
domain-containing proteins such as PDZK1 and Na+/H+ exchanger (NHE) 
regulatory factor (NHERF1, SLC9A3R1) interact with and regulate the 
function of cystic fibrosis transmembrane conductance regulator protein 
(CFTR)(Wang et al., 2000; Raghuram et al., 2001). It has also been 
clarified that accessory proteins such as 4F2hc and CD147 are required for 
functional expression of neutral amino acid transporter and 
monocarboxylate transporter (MCT) 1, respectively (Enerson and Drewes 
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2003; Halestrap and Meredith 2004; Palacin and Kanai 2004). Since the 
drug transporters are transmembrane proteins whose cell-surface 
expression should be subject to homeostatic regulation, such regulatory 
factors may indirectly influence the membrane transport of substrates 
through interaction with the transporters. 
 Finally, identification of protein interactions could provide a 
structural basis for the interactions in networks of transporters and other 
proteins. In general, active transport requires a driving force, by which a 
substrate can be concentratively transported against an electrochemical 
gradient. For example, uptake of substrates by PEPT1 utilizes an inwardly 
directed H+ gradient, which is produced by Na+/H+ exchanger (NHE). 
Uptake of substrates by organic anion transporter (OAT) 1 utilizes an 
outwardly directed gradient of dicarboxylate which is produced by the Na+ 
dicarboxylate transporter (NaDC). Therefore, to obtain efficient 
transporting activity, the appropriate driving force should be produced in 
close proximity to the drug transporters to avoid diffusive loss of the ion 
gradient. Indeed, uptake of dipeptides by the H+/oligopeptide transporter on 
the apical membrane in Caco-2 cells has been suggested to be indirectly 
controlled by NHEs, which supply the H+ gradient for this peptide uptake 
mechanism(s) (Thwaites et al., 2002). Hence, this oligopeptide transport 
system exhibits apparent Na+-dependence in its substrate uptake, and NHE 
inhibitors hinder uptake of glycylsarcosine (GlySar) in Caco-2 cells 
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(Thwaites et al., 2002; Anderson et al., 2003). Functional modulation by 
NHE can also occur intracellularly, since NHE can export H+, which is 
taken up by oligopeptide transporters. Kennedy et al. (2002) suggested that 
optimal absorptive transport of GlySar depends on the NHE activity, and 
the reliance of an oligopeptide transporter upon a Na+-dependent 
intracellular pH regulatory mechanism such as NHE may partly explain the 
apparent Na+-dependence of high-affinity dipeptide uptake observed in 
PEPT2-expressing astrocytes (Kennedy et al. 2002). Transporter-adaptor 
interactions may provide the structural basis of functional coupling of 
different transporters, as discussed later. 
 
2. PDZ binding motif in drug transporters as a signal for protein 
interaction 
2-1) PDZ interaction motif localized on C-terminus of various drug 
transporters 
 PDZ domains are generally composed of 80-90 amino acids, and 
are defined as domains commonly found in postsynaptic density 
PSD-95/SAP90, the Drosophila septate junction protein disc-large, and the 
tight junction protein ZO-1 (Hung et al., 2002; Biber et al., 2004; Brone 
and Eggermont 2005). PDZ domains are thought to play important roles in 
targeting of proteins to specific cell membranes, assembling proteins into 
signaling complexes for efficient transduction, and regulating the function 
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of transmembrane proteins (Hung et al., 2002; Biber et al., 2004; Brone 
and Eggermont 2005). PDZ domains bind to the PDZ binding motif usually 
located at the C-terminus of interacting proteins. The binding specificity of 
PDZ domains is critically determined by the amino acid located at the 
extreme C-terminus (position 0) and the amino acid at position -2. , and 
PDZ domains are classified into three groups (class I to III) based on the 
amino acid sequence in the interacting motif. 
 Some of the drug transporters which belong to the SLC 
superfamily have a class I PDZ binding motif (-S/T-X-Φ, Φ is a 
hydrophobic amino acid) at their extreme C-terminus (Table 1). 
Interestingly, most of the transporters with the class I PDZ motif in human 
and/or mouse orthologs, such as PEPT1, PEPT2, OAT4, OCT3, OCTN1, 
OCTN2, OATP-A and OATP-B, are expressed on apical membranes in 
kidney and/or small intestine (Table 1), implying that this motif could play 
a role as an apical localization signal (Russel et al., 2002). The presence of 
the PDZ binding motif in apically expressed drug transporters could be 
compatible with the idea that PDZ domain-containing proteins orchestrate 
plasma membrane retention and post endocytic sorting operations through 
interaction with membrane proteins in polarized epithelial cells (Campo et 
al., 2005). A fundamental role of the PDZ motif may also be supported by 
the fact that this motif is generally conserved between human and mouse, 
except for PEPT1 and OATP family members (Table 1). Further studies are 
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needed to clarify whether such difference in C-terminal sequences is 
relevant to differential regulation of transporters in various species. 
Although the C-terminal sequence of human PEPT1 does not exactly fit the 
class I motif, the crab-eating macaque, pig, canine, sheep, rabbit, rat and 
mouse orthologs all have the C-terminal sequence -TXM which fits a class 
I motif. The status of the PDZ motif in the OATP family is more 
controversial, probably because human OATP orthologs do not necessarily 
correspond to mouse orthologs (Hagenbuch and Meier 2003). In the 
OATP1A family, for example, OATP-A has a class I motif (Table 1), and 
the C-terminus in all the Oatp1a family members in mouse (Oatp1a1/Oatp1, 
Oatp1a4/Oatp2, Oatp1a5/Oatp3, Oatp1a6/Oatp5) is –TKL which fits a 
class I motif. In the OATP2B family, on the other hand, OATP-B has a 
class I motif (Table 1), whereas the C-terminal sequence of Oatp2b1/Oatp9 
is –QQL. 
 
2-2) Requirement of C-terminal PDZ motif for intracellular localization 
The presence of an apical sorting signal in the C-terminal region 
has been suggested for several drug transporters including MRP2. The 
MRP2 mutant with the last three amino acids (-TKF) deleted is 
predominantly localized in the basolateral membrane of MDCK cells 
(Harris et al., 2001). The deletion of 15 C-terminal amino acids results in 
impaired apical localization of MRP2 in HepG2 cells (Nies et al., 2002). 
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These results suggest that the C-terminal residues are essential for apical 
localization of MRP2. However, the MRP2 mutant with the last three 
amino acids deleted is targeted to plasma membranes of L1210 cells, 
whereas the parent construct of MRP2 is localized intracellularly (Harris et 
al., 2001), suggesting that the function of the sorting signal in transporters 
depends on the host cell type, possibly due to differences in the adaptor 
proteins interacting with the sorting signal.  
Thus, the PDZ-binding motif in MRP2 may play a role as an apical 
targeting and/or retention signal. However, it should also be noted that 
PDZ binding motifs act as a signal for targeting of at least certain types of 
proteins to subcellular compartments other than apical membranes. For 
example, basolateral sorting of ErbB receptors, potassium channel Kir 2.3 
and γ-aminobutyric acid transporter BGT-1 requires a PDZ binding motif 
in the cytosolic domain (Campo et al., 2005). Thus, to understand better the 
physiological roles of the PDZ binding motif in drug transporters, the 
nature of the interacting proteins and the physiological relevance of the 
interactions should be fully clarified. 
 
2-3) Protein-protein interaction at the PDZ binding motif 
 Until recently, information on protein-protein interactions has been 
quite limited for drug transporters. Yeast two-hybrid analysis first 
identified a specific interaction of the C-terminal cytosolic region of MRP2 
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with the PDZ domain-containing protein PDZK1 (also designated as 
Diphor-1/NaPi-Cap1/CLAMP/CAP70) (Table 2)(Kocher et al., 1999). 
Thereafter, interaction analysis by Gilser et al. (2003) revealed the 
interaction of PDZK1 with several drug transporters, including urate 
transporter (URAT1), OCTN1 and Oatp5. To examine the overall pattern 
of the interaction of drug transporters with PDZ domain-containing 
proteins, we have recently performed yeast two-hybrid interaction analysis 
of the C-terminal cytosolic region of drug transporters with four PDZ 
domain-containing proteins which are known to interact with other SLC 
superfamily members (Kato et al., 2004) (Table 1). This screening clearly 
indicated specific interactions of certain drug transporters with PDZ 
proteins, and all the drug transporters that showed a positive interaction 
have a PDZ binding motif at their C-terminus (Table 1), suggesting that 
these C-terminal motifs act as a signal for specific interaction. These PDZ 
proteins include PDZK1, PDZK2 (also named NaPiCap2, and intestinal 
and kidney-enriched PDZ protein, IKEPP), NHERF1 and NHERF2 
(SLC9A3R2, also named E3KARP, SIP-1 and TKA-1)(Table 1, Fig. 2). 
The interaction was confirmed by using recombinant C-terminal regions 
and PDZ proteins (Gisler et al., 2003; Anzai et al., 2004; Kato et al., 2004, 
2005). 
 PDZK1 and PDZK2 have four PDZ domains in its structure (Fig. 
2), each PDZ domain having been proposed to bind independently to a 
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PDZ motif (Table 2). Yeast two-hybrid and pull-down studies using 
recombinant proteins have identified a number of interacting membrane 
proteins for each PDZ domain in PDZK1 (Table 2). Some of the membrane 
proteins can bind to only a single PDZ domain in PDZK1, whereas others 
can bind to 2 or 3 PDZ domains (Table 2, Fig. 2). For example, the 
C-terminal region in CFTR binds to PDZ3 with high affinity (Kd = 8 nM), 
and to PDZ1 and PDZ4 with low affinity (Kd = 100-200 nM), but does not 
bind to PDZ2 (Wang et al., 2000) (Table 2, Fig. 2). Similarly, the 
C-terminal domain in URAT1 binds to PDZ1 with high affinity (Kd = 2 
nM), and to PDZ2 and PDZ4 with low affinity (Kd = 300-500 nM), but 
does not bind to PDZ3 (Anzai et al., 2004) (Table 2, Fig. 2). The 
physiological relevance of such multiple binding domains in PDZK1 for 
each transporter has not yet been clarified, except that the tandem PDZ 
domains interacting with CFTR are essential for functional modulation by 
PDZK1 (Wang et al., 2000). The interaction potential among multiple 
domains may allow fine functional regulation of drug transporters. 
Immunohistochemical and biochemical analyses have indicated 
that both PDZK1 and several drug transporters are colocalized on apical 
membranes of renal proximal tubular epithelial cells (Gisler et al., 2003; 
Anzai et al., 2004; Kato et al., 2004, 2005). In addition, NHERF1 can also 
bind to NHERF1 itself, NHERF2 and PDZK1 (Gisler et al., 2003; Lau and 
Hall 2001). These results suggest that drug transporters may be localized 
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within a large protein complex consisting of several PDZ proteins (Gisler 
et al., 2003; Kato et al., 2004). Although the physiological significance of 
such a network should be clarified by further analysis, it may provide a 
structural basis for functional coupling of drug transporters. For example, 
PEPT2 might be localized in close proximity to NHE3, a Na+/H+ exchanger 
which is expressed on apical membranes of renal proximal tubules, because 
PDZK1 can bind to PEPT2 and NHE3 at different PDZ domains (Table 2, 
Fig. 3). Alternatively, NHE3 may bind to NHERF1, which can then 
interact with PEPT2 indirectly through PDZK1 (Table 2, Fig. 3). Therefore, 
a precise understanding of the structural organization of each transporter 
protein could be important for estimating membrane transport efficacy for 
various substrates at apical membranes in the kidney.   
 Protein-protein interaction and protein network formation in the 
kidney have been extensively studied for NHE3, and the results indicate 
colocalization of NHE3 with other membrane proteins.  These proteins 
include megalin, which belongs to the LDL receptor superfamily and is 
involved in renal reabsorption of various compounds and polypeptides, and 
dipeptidyl peptidase-IV (DPPIV, also known as CD26), which is a highly 
specific serine protease that cleaves N-terminal dipeptides from peptides 
with a penultimate proline or alanine (Biemesderfer et al., 1999; Girardi et 
al., 2001). It should be noted however, that this network consists of distinct 
compartments, since NHE3 antibody can immunoprecipite DPPIV, but not 
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sodium-phosphate cotransporter (NPT) 2, which is also expressed on apical 
membranes of renal proximal tubules, and can interact with NHERF1 and 
PDZK1 (Gisler et al., 2001) (Table 2). DPPIV and megalin can be 
independently co-precipitated with NHE3 by different NHE3 antibodies 
(Biemesderfer et al., 1999; Girardi et al., 2001), also supporting such 
distinct compartmentalization. In addition, Although protein-protein 
interaction studies have suggested possible formation of large protein 
complexes consisting of multiple transporters and PDZ proteins, no study 
has actually isolated or visualized such a complex. Thus, details of the 
organization of these membrane transporters remain to be clarified. 
The PDZ binding signal in MRP2 also matches the protein kinase 
(PK) C phosphorylation site designated as [S/T]-X-[R/K]. Hegedus et al. 
(2003) reported, based on in vitro binding experiments, a high interaction 
potential with NHERF1 of the phosphorylated C-terminal peptide of MRP2. 
This may be compatible with the previous finding that PMA treatment 
resulted in mistargeting of MRP2 to the basolateral membrane in HepG2 
cells (Kubitzb et al., 2001). Thus, at least certain types of PDZ 
domain-PDZ binding motif interaction may not represent just physical 
interaction, but may also be involved in regulation of intracellular 
trafficking and/or signaling. 
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3. PDZ adaptor proteins involved in regulation of expression and 
function of transporters 
3-1) PDZK1 family: Structure, expression and localization 
Both PDZK1 and PDZK2 have four PDZ domains in their 
structure (Fig. 2) and they have 28% amino acid sequence identity in the 
case of the human orthologs. Since no other distinct structure than PDZ 
domains have been defined in these PDZK family proteins, these can be 
categorized as simple adaptors (Bezprozvanny and Maximov 2001) (Fig. 2). 
The primary structure of PDZK1 is highly conserved among mammalian 
species, with 78% identity between the human and mouse orthologs. This 
is also the case for PDZK2, since human PDZK2 has 81% identity with 
mouse NaPiCap2, which is probably the mouse ortholog for PDZK2. 
PDZK1 was identified by differential display-PCR techniques as a 
protein which is up-regulated in rats on a low-phosphate diet, and it 
increased the phosphate-transporting activity of NPT2 transfected into 
Xenopus laevis oocytes (Custer et al., 1997). PDZK1 was also identified as 
a PDZ domain-containing protein which is up-regulated in several 
carcinoma cell lines (Kocher et al., 1999) or increases cell-surface 
expression of HDL receptor scavenger receptor class B type I (SR-B1) 
(Ikemoto et al., 2000).  
On the other hand, PDZK2 was first identified as NaPiCap2 in an 
adult mouse kidney cDNA library by yeast two-hybrid screening as an 
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interacting partner for NPT2a (Gisler et al., 2001). Human PDZK2 was 
also identified by yeast two-hybrid screening as a regulator of guanylyl 
cyclase C, the heat-stable enterotoxin receptor (Scott et al., 2002). Thus, 
both PDZ proteins may interact with various types of cellular proteins. 
In northern blot analysis, PDZK1 was detected in mouse liver, 
kidney, small intestine and testis, whereas PDZK2 was expressed only in 
kidney and small intestine (Gisler et al., 2001). Western blot analysis in 
mouse tissues revealed higher expression of PDZK1 in kidney, followed by 
liver and jejunum, significant expression being also observed in brain, lung 
and testis (Wang et al., 2000). In mouse kidney both PDZK1 and PDZK2 
are immunostained on apical membranes exclusively in proximal tubules, 
and the immunostaining was uniform along the proximal tubules (S1, S2, 
and S3 segments) (Gisler et al., 2001). PDZK1 is strictly associated with 
the microvilli, whereas PDZK2 is predominantly located in the subapical 
compartment, faint immunostaining being also found throughout the 
cytoplasm, but not in the microvilli (Gisler et al., 2001). 
In rabbits, mRNA and protein expression of PDZK1 is much lower 
in the colon than in the small intestine (Rossmann et al., 2005). On the 
other hand, in humans, gene expression of PDZK1 assessed by Northern 
blot analysis was observed in kidney, liver and small intestine (Wang et al., 
2000). Northern blot analysis revealed PDZK2 mRNA expression almost 
exclusively in the kidney, with much lower levels in the small intestine and 
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colon in humans. Immunohistochemical analysis revealed localization of 
PDZK2 on the apical surface in cells of the crypt and villus of human ileum 
and colon (Scott et al., 2002). Overall, these two PDZK1 family members 
are expressed on apical membranes in both kidney and small intestine of 
each species, although distinct localizations may also occur and be relevant 
to their specific physiological roles. 
 
3-2) NHERF family: Structure, expression and localization 
NHERF1 was first purified by means of biochemical techniques 
and cloned as a protein kinase A-mediated regulator of NHE in rabbit renal 
brush border membranes, whereas NHERF2 was identified by yeast 
two-hybrid analysis as a protein interacting with the C-terminal 
cytoplasmic region of NHE3 (Weinman et al., 1993, 1995; Yun et al., 
1997). NHERF1 has high homology with NHERF2 (~52% identity for the 
human orthologs), both having two PDZ domains at the N-terminal side 
(Fig. 2). In contrast to the PDZK1 family members, which have only four 
tandem PDZ domains in their structure (Fig. 2), NHERF1 and NHERF2 
also have an ERM (ezrin-radixin-moesin) binding domain at their 
C-terminal region, which can directly bind to the FERM (band 
four-point-one, ERM) domain located at the N-terminal region of ERM 
family members (Bretscher et al., 2000, 2002; Voltz et al., 2001) (Fig. 2). 
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In that sense, these NHERF family proteins can be categorized as complex 
adaptors (Bezprozvanny and Maximov 2001). 
NHERF1 and NHERF2 can form both homo- and 
hetero-oligomers, and Oligomerization of NHERF1 and NHERF2 is 
differentially regulated: NHERF1/NHERF1 association has a relatively 
lower affinity, but has a higher affinity in the presence of the C-terminal 
ligand of transmembrane proteins, and it can be affected by a constitutively 
phosphorylated serine residue within NHERF1, whereas 
NHERF2/NHERF2 association has a relatively higher affinity and is only 
minimally affected by interaction with the C-terminal ligand (Lau and Hall 
2001). Such characteristics of the intermolecular interactions may be 
important for stabilization of membrane proteins including transporters, in 
cell-surface membranes. 
In the mouse, western blot analysis revealed strong expression of 
NHERF1 both in kidney and small intestine, with intermediate levels being 
observed in liver and stomach; NHERF2 protein is expressed abundantly in 
the lung, but its expression in the above organs is quite low (Ingraffea et al., 
2002). In humans, mRNA expression, assessed by northern blot analysis, of 
both NHERF1 and NHERF2 was ubiquitous, except that NHERF1 mRNA 
was absent in lung and skeletal muscle (Yun et al., 1997). 
Immunohistochemical analyses of NHERF family members have 
revealed their apical localization in kidney and small intestine, but 
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localization in other subcellular compartments is also likely: in rat kidney, 
NHERF1 is immunostained most abundantly in the apical brush-border 
membrane, cytosol and, to a lesser degree, in the basolateral membranes of 
renal proximal tubules, but is not expressed in any other nephron structures 
(Wade et al., 2001). On the other hand, NHERF2 is strongly detected in the 
glomerulus and other vascular elements, and in the cortical and medullary 
collecting ducts, but is not clearly immunostained in proximal tubules 
(Wade et al., 2001). The predominant expression of NHERF1, but not 
NHERF2, in proximal tubules was also reported in mouse kidney 
(Ingraffea et al., 2002). Mouse proximal tubules express both NHERF1 and 
NHERF2, but NHERF1 is strongly expressed in microvilli in association 
with ezrin, whereas NHERF2 is weakly detected in the microvilli, but is 
expressed predominantly at the base of the microvilli in the vesicle-rich 
domain (Wade et al., 2003). 
Immunohistochemical analysis in the rabbit small intestine 
revealed localization of NHERF1 on ileal brush border membranes (Kim et 
al., 2002). Localization of NHERF1 in the brush border of columnar 
epithelial cells in the small intestine was also found in mouse, with striking 
colocalization with ezrin (Ingraffea et al., 2002). In rat liver, NHERF1 is 
expressed on the apical domain of hepatocytes, whereas NHERF2 
expression in hepatocytes was hardly detected (Fouassier et al., 2001). In 
mouse liver, NHERF1 is expressed in bile canaliculi of hepatocytes, 
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colocalizing with radixin, while expression of NHERF2 was not detected 
(Ingraffea et al., 2002).  
 
3-3) Effect of PDZ proteins on membrane transport in vitro 
 Experimental findings in vitro have suggested that PDZK1 directly 
regulates the cell-surface expression and/or functional activity of various 
types of transporters. Custer et al. (1997) first reported increased phosphate 
transport by NPT2 in the presence of PDZK1. Wang et al. (2000) 
suggested that PDZK1 promotes intermolecular interaction of CFTRs, 
leading to potentiation of the chloride channel activity. The C-terminus of 
CFTR can interact with three of the four PDZ domains (PDZ1, PDZ3 and 
PDZ4) in PDZK1 (Fig. 2, Table 2, Wang et al., 2000). Interestingly, a 
stimulatory effect on channel activity was seen with a bivalent monoclonal 
antibody for CFTR and PDZ3-4 of PDZK1, but not with PDZ1-2, PDZ2-3 
nor PDZ3, suggesting that linkage of at least two CFTR molecules via the 
C-terminus is necessary for the stimulatory effect (Wang et al., 2000).  
Such bivalent PDZ domain-mediated functional modulation of CFTR was 
also observed with NHERF1 (Raghuram et al., 2001).  
 Regarding the stabilization of drug transporters, Anzai et al. 
(2004) found that coexpression of PDZK1 increases transport capacity for 
urate by URAT1 in HEK293 cells, and such an increase can be explained 
by an increase in cell-surface expression of URAT1 induced by PDZK1. 
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On the other hand, transport of GlySar by PEPT2 and carnitine by OCTN2 
was increased in HEK293 stably expressing PDZK1, and such an increase 
cannot be explained by the change in mRNA for PEPT2 or cell-surface 
expression of OCTN2, respectively (Kato et al., 2004, 2005). Coexpression 
of PDZK1 results in an approximately 6-fold increase in transport capacity 
for carnitine by OCTN2 with minimal change in transport affinity, whereas 
modulation of the transport function by PDZK1 is less marked for PEPT2 
and URAT1 (Kato et al., 2004, 2005; Anzai et al., 2004). In all cases, 
transporter mutants with deletion of the last three or four amino acids at the 
C-terminus exhibited no increase in activity in the presence of PDZK1, 
suggesting that interaction of PDZK1 with the transporters is responsible 
for the stabilization and functional regulation of the transporters by PDZK1 
(Anzai et al., 2004; Kato et al., 2004, 2005). In addition, PDZK1 is 
colocalized with URAT1 and OCTN2 on apical membranes in proximal 
tubules in kidney, and pull-down assay or immunoprecipitation also 
suggested the colocalization of those transporters with PDZK1 in vivo 
(Anzai et al., 2004; Kato et al., 2005). However, all the experimental 
evidence suggesting the modulation of drug transporters by PDZK1 has 
been obtained in vitro, except that essential role of PDZK1 in basolateral 
expression of Oatp1a1/Oatp1 in hepatocytes was recently demonstrated in 
vivo using PDZK1 knockout mice (Wang et al., 2005). 
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Considering that cell-surface expression and/or functional activity 
of transporters are directly regulated by the PDZ proteins, at least in vitro, 
endogenous expression of the PDZ proteins may affect the expression 
and/or function of transporters either endogenously expressed or 
exogenously transfected in the cell lines used for in vitro assays. Actually, 
it has been demonstrated that PDZ domain-NPT2a interaction is essential 
for apical localization of the transporter in LLC-pK1 cells (Hernando et al., 
2002). As shown in Table 3, endogenous expression of the four PDZ 
domain-containing proteins is relatively ubiquitous in various cell lines. 
This may at least partially explain the apparently functional expression of 
drug transporters in most cell lines (CHO, LLC-pK1, HEK293, HeLa, etc) 
that have been usually used for in vitro analysis of drug transporters (Table 
3). However, it is sometimes observed that transporters exogenously 
transfected into cell lines do not express their proper function and/or are 
not targeted to plasma membranes. For example, endogenous NPT2a and 
exogenously transfected NPT2a are properly targeted to apical membranes 
in OK cells, whereas NPT2 transfected into LLC-pK1 cells is mainly 
localized on apical membranes, but weak expression is also found in the 
basolateral region (Hernando et al., 2000). On the other hand, NPT2a 
transfected into MDCK cells is detected equally at basolateral and apical 
membranes, and that transfected into Caco2 cells does not reach the 
membranes, but remains in the cytoplasm (Hernando et al., 2000, 2001). 
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 3-4) Gene knockout mice for assessing the physiological roles of PDZ 
proteins 
Considering that PDZK1 can interact with various types of 
transporters through multiple PDZ domains in its structure and thereby 
regulate the expression and/or function of the membrane proteins (Fig. 2, 
Table 2), changes in the gene expression level of PDZK1 could possibly 
affect the expression and/or localization of membrane transporters, 
consequently affecting the membrane transport kinetics of various types of 
compounds. As a promising approach to analyze the physiological roles of 
PDZ proteins, PDZK1 gene knockout mice were first developed by Kocher 
et al. (2003a).  PDZK1-deficient mice developed normally, did not 
display any gross phenotypic abnormalities, and exhibited apparently 
normal immunohistochemical localization of MRP2 and NPT2a in the 
kidney, probably due to functional compensation by other PDZ proteins 
(Kocher et al., 2003a). However, they exhibit an approximately two-fold 
elevation of plasma total cholesterol level, which is thought to result from a 
95% reduction in the HDL receptor scavenger receptor class B type I 
(SR-B1) gene product in the liver, with only a minimal change in its 
mRNA level (Kocher et al., 2003b). 
In the PDZK1 knockout mouse, expression of NPT2a is decreased 
under a high-Pi diet condition, with a concomitant higher urinary fractional 
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Pi excretion (Capuano et al., 2004). In the NHERF1 gene knockout mouse, 
on the other hand, NPT2 expression on brush border membranes in the 
kidney is lower than that in the wild-type mouse, NPT2 being aberrantly 
localized at internal sites in the renal proximal tubule cells, concomitantly 
with a higher urinary excretion of phosphate (Weinman et al., 2003a; 
Shenolikar et al., 2002). Although the NHERF1 knockout mouse exhibited 
normal blood electrolytes, smaller body weight than in the wild-type mouse 
was observed in females, and disorganized microvilli were seen in the 
small intestine (Morales et al., 2004). Thus, both NHERF1 and PDZK1 
could be involved in cell-surface stabilization and/or expression of NPT2 at 
least under some conditions. In humans, NHERF1 is also expressed in the 
uppermost stratum granular layer of epidermis, and SNP in a putative 
RUNX1 binding site close to the NHERF1 gene is associated with psoriasis 
(Helms et al., 2003). Recent biopharmaceutical analysis has revealed 
functional expression of drug transporters in the skin (Li et al., 2005). 
Further analysis of the association of NHERF1 and drug transporters 
should improve our understanding of drug permeation in the skin. 
 
3-5) Regulation of PDZ proteins 
PDZ proteins can interact with other cellular proteins besides 
transporters, implying that transporter-PDZ protein interactions lead to 
further protein network formation. Both PDZ1 and PDZ4 in PDZK1 have 
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been reported to interact with MAP17 (17-kD membrane-associated protein, 
also known as DD96, SPAP and pKe#192), which is expressed in the 
proximal tubules of the kidney cortex, spermatids of the seminiferous 
tubules and upper stratum granulosum of normal epidermis keratinocytes 
(Blasco et al., 2003; Jaeger et al., 2000). Human MAP17 has 114 amino 
acids with a PDZ binding motif (-TPM) at the extreme C-terminus. MAP17 
spans the cellular membranes twice, with both the N- and C-termini being 
inside the cells (Blasco et al., 2003). MAP17 was first identified by means 
of a differential display technique as a molecule highly up-regulated in 
human renal cell carcinoma (Kocher et al., 1995).  MAP17 seems to 
exhibit specific interaction with PDZK1, since GST fusion protein only 
with PDZK1, but not with PDZK2 or NHERF1 can pull-down MAP17 in 
renal brush border membrane vesicles (Pribanic et al., 2003).  
MAP17 is co-immunoprecipitated with PDZK1 both in liver and 
kidney of mouse (Silver et al., 2003), suggesting an interaction of the two 
proteins in vivo.  MAP17 exhibited apical localization after transfection 
into OK cells, showing colocalization with endogenous NPT2a (Pribanic et 
al., 2003). On the other hand, PDZK1 showed a cytoplasmic distribution 
when transfected alone into OK cells, whereas coexpression of PDZK1 
with MAP17 resulted in apical colocalization of the two proteins (Pribanic 
et al., 2003). Deletion of the last three amino acids in MAP17 shifted its 
subcellular localization into both apical and cytoplasmic regions, but it still 
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exhibited colocalization with PDZK1 (Pribanic et al., 2003). Thus, 
localization of PDZK1 is regulated by MAP17, at least in transfectant 
systems with in vitro cell lines. On the other hand, in vivo overexpression 
of MAP17 results in the absence of PDZK1, without any effect on 
expression of PDZK2, in mouse liver (Silver et al., 2003). In kidney, 
PDZK1 is equally distributed throughout the whole proximal tubules 
(Pribanic et al., 2003), whereas MAP17 exhibited higher apical localization 
in S1 than S3 segments (Pribanic et al., 2003). Further studies are needed 
to establish the physiological significance of the MAP17-PDZK1 
interaction in vivo. 
On the other hand, both NHERF1 and NHERF2 have an ERM 
binding domain at their C-terminal region (Fig. 2); this can bind directly to 
the FERM (band four-point-one, ERM) domain located at the N-terminal 
region in members of the ERM family (Bretscher et al., 2000, 2002; Voltz 
et al., 2001). The FERM domain can also interact directly with C-ERMAD 
(C-terminal ERM association domain) in ERM proteins, forming an 
inactive state. Activation of ERM protein is accomplished by C-terminal 
phosphorylation, resulting in relief of the FERM/C-ERMAD interaction 
and regeneration of interaction potential of FERM with NHERFs. This 
activation is compatible with the observation of high levels of 
phosphorylated ERM proteins in membrane fractions in both kidney and 
intestine (Morales et al., 2004). The C-terminal region in ERM proteins can 
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interact with filamentous (F)-actin, suggesting a fundamental role in the 
structural organization of polarized epithelial cells by connecting F-actin to 
plasma membrane proteins, including transporters. Ezrin is highly 
expressed both in kidney and small intestine, whereas radixin is the major 
ERM protein in liver.  
Interestingly, expression of ezrin, especially phosphorylated ezrin, 
on brush membranes in both kidney and small intestine is clearly 
down-regulated in NHERF1 gene knockout mouse, demonstrating that 
NHERF1 is required for the maintenance of activated ezrin on brush border 
membranes (Morales et al., 2004). In small intestine where ezrin is the only 
ERM protein expressed, disorganized microvilli with an increase in the 
number of goblet cells are observed in NHERF1 knockout mice, suggesting 
a physiological role of NHERF1 in apical membrane organization (Morales 
et al., 2004). In radixin knockout mouse, the serum concentration of 
conjugated bilirubin is increased compared with wild-type mouse, showing 
a similar phenotype to human conjugated hyperbilirubinemia in 
Dubin-Johnson syndrome (Kikuchi et al., 2002), which results from genetic 
deficiency in MRP2 
 
4. Involvement of PPAR-α in gene expression of drug transporters and 
PDZ proteins 
- 29 - 
PPARα is a member of the large nuclear receptor superfamily and 
regulates expression of genes responsible for fatty acid β-oxidation and 
energy homeostasis. PPARα is highly expressed in liver, heart muscle, 
kidney and skeletal muscle, which have relatively high mitochondrial and 
peroxisomal fatty acid β-oxidation rates. PPARα agonists include fibric 
acid derivatives (fibrates), nonsteroidal anti-inflammatory drugs, and 
saturated and unsaturated fatty acids. PPARα is also activated by 
glucocorticoids and fasting. Expression of Mdr2mRNA was 5-fold 
increased in fasted wild-type mice, but increased only marginally in 
PPARα (-/-) mice. Fibrates have been used to treat dyslipidemia because 
they increase high-density lipoprotein cholesterol (HDL) and decrease 
triglyceride in serum (Berger et al., 2005; van Raalte et al., 2004; 
Goikoetxea et al., 2004). PPARα is the target of drugs that are effective in 
the treatment of metabolic disorders (atherogenesis, cardiovascular disease, 
type 2 diabetes, etc.). PPARα/γ dual agonists are also being developed.  
Repeated administration of fibrates such as ciprofibrate and 
fenofibrate caused almost complete down-regulation of PDZK1 and SR-B1, 
and this mainly occurs via PPARα since PPARα (-/-) mice exhibited no 
down-regulation (Mardones et al., 2003). Considering that SR-B1 is the 
major HDL receptor in liver and its cell-surface expression is highly 
regulated by PDZK1, the down-regulation of SR-B1 could be at least 
partially due to the down-regulation of PDZK1, and could explain in part 
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the increase in HDL level after treatment with fibrates. However, a recent 
finding indicated the presence of a PDZK1-independent pathway for 
SR-B1 down-regulation (Lan et al., 2005), suggesting the presence of other 
molecular machinery for stabilizing SR-B1 in hepatocytes. 
After treatment of mice with PPARα agonists such as clofibrate, 
ciprofibrate and di(2-ethylhexyl)phthalate, the mRNAs for hepatic 
transporters, Oatp1a1/Oatp1, Oatp2a1/PGT and Oatp2b1/Oatp9, were 
decreased, whereas that for Mrp3 was increased without any significant 
change in that for Mrp2 (Cheng et al., 2005; Maher et al., 2005). Such 
down-regulation of Oatp1a1/Oatp1 was previously reported at both the 
mRNA and protein levels in mouse liver, and such transcriptional 
regulation occurs via PPARα-activation (Kok et al., 2003). On the other 
hand, ciprofibrate treatment increases expression of Oatp1a1/Oatp1, with a 
decrease in Mrp2, as revealed by Western blot analysis of hepatic 
membrane fraction in rats (Chandra et al., 2005), suggesting species 
difference in PPARα activation. The efflux of a non-metabolized model 
substrate, 5(and 6)-carboxy-2',7'dichlorofluorescein (CDF) from liver to 
bile was found to be decreased in a rat liver perfusion system, and this 
could be compatible with the down-regulation of Mrp2 (Chandra et al., 
2005). On the other hand, hepatic uptake of CDF is decreased after 
clofibrate treatment, and this cannot be simply explained by up-regulation 
of Oatp1a1/Oatp1 (Chandra et al., 2005). Both rat and mouse 
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Oatp1a1/Oatp1 interacts with PDZK1, and PDZK1 is responsible for 
sinusoidal localization of Oatp1a1/Oatp1, as revealed in PDZK1 gene 
knockout mouse (Wang et al., 2005). Considering down-regulation of 
PDZK1 by treatment with fibrates (Mardones et al., 2003), mislocalization 
of Oatp transporters by the down-regulation of PDZK1 might be involved 
in the change in hepatic membrane transport by the fibrate treatment.  
Juvenile visceral steatosis (jvs) mice which have a hereditary 
deficiency of the OCTN2 gene exhibit fat deposition and mitochondrial 
abnormalities in the liver. The high-affinity site for uptake of carnitine was 
absent in hepatocytes obtained from jvs mouse (Yokogawa et al., 1998). 
Considering that carnitine is efficiently transported by OCTN2, these 
results suggest that OCTN2 is functionally expressed in sinusoidal 
membranes of hepatocytes and is possibly involved in lipid homeostasis via 
transport of carnitine, which is essential for β-oxidation of fatty acids. 
Considering that PDZK1 is a functional modulator of OCTN2, 
down-regulation of PDZK1 after treatment with fibrates may affect 
carnitine uptake by OCTN2, leading to a change in fatty acid metabolism. 
Further studies are needed to clarify the pharmacological significance of 
the OCTN2/PDZK1 system in energy homeostasis in liver.  
       There are large species differences in the expression of PPARα. 
Human liver has less than one-tenth the levels of PPARα expression 
observed in mice and rats. Therefore, PPARα-mediated gene activation in 
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 Recent progress in the analysis of protein-protein interactions has 
revealed that the expression and/or function of at least some types of drug 
transporters are regulated by PDZ domain-containing proteins. Various 
transporters localized at apical membranes in kidney and small intestine are 
thought to be incorporated into protein networks (Fig. 3). Drug transporters 
are categorized in several families, and often have overlapping substrate 
specificity and cellular localization in the body, suggesting the presence of 
functional redundancy. Similarly, PDZ proteins have overlapping binding 
specificity (Table 1) and cellular localization, and data obtained in gene 
knockout mice suggest the occurrence of compensation of physiological 
function. Considering the multiple interactions between PDZ domains and 
cytosolic domains of various transporters, PDZ proteins have the potential 
to influence membrane transport of many substrates, possibly affecting 
disposition of these substrates in the body. The physiological roles of PDZ 
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FIGURE LEGENDS 
Fig. 1  Schematic diagram representing transporter-mediated 
vectorial transport of xenobiotics and nutrients in renal proximal 
tubules. 
 
Fig. 2 PDZ domain-containing proteins which bind to drug 
transporters of the SLC superfamily  
 Activated ERM (ezrin-radixin-moesin) can interact with ERM 
binding domain (ERMB) located at the C-terminus of NHERF1 and 
NHERF2. ERM can also bind to protein kinase A (PKA) and β-actin. 
 
Fig. 3  Schematic diagram representing protein-protein interactions 
of various types of transporters and PDZ adaptors  
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Table 1.  C-terminal sequence, tissue localization and protein interaction of drug transporters of the 
SLC superfamily in humans and mice
Localizationb)C-Terminusa)










































































PDZK1 PDZK2 NHERF1 NHERF2
(-)
(-)           (+)        (-) (-)
(+)       (+)           (-) (-)
a) The C-terminal sequences for human and mouse orthologs are based on NCBI reference sequences. The class 
I PDZ binding motif is shown in bold. The mouse ortholog for OAT4 has not been reported, and those for 
OATP family members are not shown due to incomplete 1:1 correspondence between human and mouse.
b) Localization observed in human and/or rodents.  OAT2 is localized on basolateral and apical side of proximal 
tubules in human and rats, respectively.
) D t bt i d f h t t it d f K t t l (2004)
Human    Mouse
(-)       (-)        (-) (-)
(+)   (+)    (+) (+)
(-)       (-)        (-) (-)
(-)           (+)        (-) (-)
(-) (-)        (-) (-)
(-)       (-)        (-) (-)
(-)       (-)        (-) (-)
(+)   (+)    (+) (+)
(+)    (+)        (+/-) (+/-)
(-)       (-)        (-) (-)
(-)     (+)      (+/-) (+/-)
(-)        (+/-)      (-) (-)
(-) (-)        (-) (-)
(-) (-)        (-) (-)
(-) (-)        (-) (-)
(+)   (+)    (+) (+)
PDZ Domains Proteins Sequencesc) References
PDZ1 BCR -STEV Malmberg et al ., 2004
SR-B1a) -EAKL Ikemoto et al ., 2000
URAT1 -STQF Anzai et al ., 2004
MRP2 -STKF Kocher et al ., 1999
MAP17 -STPM Kocher et al ., 1999
NHE3 -STHM Gisler et al ., 2003
CFTR -DTRL Wang et al ., 2000
PDZ2 OCTN1 -ITAF Gisler et al ., 2003
OCTN2 -STAF Kato et al ., 2005
URAT1 -STQF Anzai et al ., 2004
PEPT2 -KTKL Kato et al ., 2004
UBC9b) -FAPS Gisler et al ., 2003
DRA -ETKF
Gisler et al ., 2003; Rossmann
et al ., 2005
PDZ3 NPT1 -HTRL Gisler et al ., 2003
NPT2 -ATRL
Custer et al ., 1997; Gisler et
al ., 2001, 2003
PEPT2 -KTKL Kato et al ., 2004
Oatp5 -KTKL Gisler et al ., 2003
CFEX -VTRL Gisler et al ., 2003
DRA -ETKF
Gisler et al ., 2003; Rossmann
et al ., 2005
CFTR -DTRL Wang et al ., 2000
SLKb) -STGS Gisler et al ., 2003
PDZ4 URAT1 -STQF
Gisler et al ., 2003; Anzai et
al ., 2004
OCTN1 -ITAF Kato et al ., 2005
OCTN2 -STAF Kato et al ., 2005
MAP17 -STPM
Kocher et al ., 1999; Gisler et
al. , 2003
NHERF1 -FSNL Gisler et al ., 2003
NHERF2 -FSNF Gisler et al ., 2003
CFTR -DTRL Wang et al ., 2000
D-AKAP2/AKAP10 -STKL Gisler et al ., 2003
Table 2.  Interaction of each PDZ domain in PDZK1 with C-
terminal domain sequences of several membrane proteins.
a) PDZ1 and approximately 40 amino acids residues following PDZ1 are
necessary for the interaction.
b) These proteins were found to be expressed only in the cytosol.
c) The extreme C-terminal sequences of the human orthologs of proteins
interacting with PDZK1 are shown, except for the Oatp5 sequence, which is
that of the mouse ortholog.
